Baidu
map

Cell Metab:TCA代谢产物能否促进干细胞自我更新也要看“状态”

2016-08-06 佚名 生物谷

 近日来自美国加州大学洛杉矶分校的研究人员在国际学术期刊Cell Metabolism上发表了一项最新研究进展,他们发现三羧酸循环中间代谢产物能够影响人类多能干细胞的分化过程,并且这种影响依赖于干细胞的多能性状态。该研究对于如何维持干细胞自我更新抑制分化提供了重要信息。 众所周知多能干细胞能够自我更新或从原始态以及更进一步的分化状态--始发态开始进行分化,目前可以通过特定的培养

 
近日来自美国加州大学洛杉矶分校的研究人员在国际学术期刊Cell Metabolism上发表了一项最新研究进展,他们发现三羧酸循环中间代谢产物能够影响人类多能干细胞的分化过程,并且这种影响依赖于干细胞的多能性状态。该研究对于如何维持干细胞自我更新抑制分化提供了重要信息。
 
众所周知多能干细胞能够自我更新或从原始态以及更进一步的分化状态--始发态开始进行分化,目前可以通过特定的培养条件获得始发态多能干细胞。有研究表明增加细胞内α-酮戊二酸(αKG)能够促进原始态小鼠胚胎干细胞的自我更新。但是αKG或αKG /琥珀酸的水平对始发态人类多能干细胞以及小鼠外胚层干细胞分化的影响仍然不清楚。
 
在这项研究中研究人员对始发态人类多能干细胞以及小鼠外胚层干细胞进行了检测,结果发现αKG增加或αKG /琥珀酸的比例增加都会加速始发态多能干细胞的分化,而琥珀酸水平增加则会导致相反的结果。
 
有研究证明αKG能够抑制线粒体ATP合酶,还可以调节起表观遗传修饰作用的双加氧酶。研究人员发现线粒体解偶联不会阻碍αKG对始发态人类多能干细胞分化的促进作用,并且αKG能够诱导始发态多能干细胞发生组蛋白和DNA的去甲基化,而琥珀酸则会干扰这一过程。
 
综上所述这项研究表明αKG对干细胞自我更新和分化过程的影响取决于干细胞的多能性状态。该研究为多能干细胞的实验研究以及临床应用提供了重要信息。

原始出处

Tara TeSlaa1, Andrea C. Chaikovsky2, Inna Lipchina3, Sandra L. Escobar4, Konrad Hochedlinger3, Jing Huang1, 5, 6, Thomas G. Graeber5, 6, 7, 8, Daniel Braas5, 7, Michael A. Teitell.α-Ketoglutarate Accelerates the Initial Differentiation of Primed Human Pluripotent Stem Cells.Cell Metab.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
    2016-09-27 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
    2017-05-16 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
    2016-09-14 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]
    2017-04-23 paperyu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1895946, encodeId=423d18959466e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Sep 27 04:20:00 CST 2016, time=2016-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959755, encodeId=44cd1959e5573, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue May 16 04:20:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887561, encodeId=bb83188e561ed, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Sep 14 06:20:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805373, encodeId=37a718053e340, content=<a href='/topic/show?id=9d42e801133' target=_blank style='color:#2F92EE;'>#细胞自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78011, encryptionId=9d42e801133, topicName=细胞自我更新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 10 02:20:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869496, encodeId=e467186949633, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jun 23 05:20:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659303, encodeId=140a1659303f8, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Fri Nov 04 11:20:00 CST 2016, time=2016-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685351, encodeId=d546168535101, content=<a href='/topic/show?id=66011e19807' target=_blank style='color:#2F92EE;'>#TCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17198, encryptionId=66011e19807, topicName=TCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766728143581, createdName=paperyu, createdTime=Sun Apr 23 19:20:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513436, encodeId=8c15151343630, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Mon Aug 08 10:20:00 CST 2016, time=2016-08-08, status=1, ipAttribution=)]

相关资讯

盘点:干细胞的临床治疗取得突破性进展一览表

2016年过半,免疫细胞治疗肿瘤取得了突破性进展,尤其是CAR-T疗法在多个临床研究中都取得了良好效果,在实体瘤的治疗上也取得一定的进展,未来FDA很可能会批准诺华CAR-T治疗药物CTL019上市,将成为世界首个CAR-T治疗药物。目前,传统的免疫细胞治疗已经在肿瘤治疗方面凸显疗效,而干细胞的临床治疗也在心血管系统疾病、糖尿病、退行性疾病、自身免疫性疾病等重大疾病中得到应用研究,取得一系列临

CCR:干细胞加速罕见癌症治疗药物筛选

最近来自美国约翰斯霍普金斯Kimmel癌症中心的研究人员利用人类干细胞开发出一个药物筛选新系统,可能会加速对罕见癌症治疗药物的筛选过程。 相关研究发表在国际学术期刊Clinical Cancer Research上。 在这篇文章中研究人员详细描述了他们如何将人类干细胞转变为一种侵袭性罕见儿童脑癌——成神经管细胞瘤。随后再将这些癌细胞的遗传信息与成百上千种已经用于药物筛选的常见人类癌细胞进行

上海交大团队在雌性生殖干细胞研究中取得新进展

来自上海交通大学生物医学工程学院和Bio-X研究院的研究人员通过对小鼠雌性生殖干细胞表观遗传修饰谱的研究,发现了决定小鼠雌性生殖干细胞基本生物学特性的表观遗传调控机制,这一研究成果于2016年7月27日在Genome Biology杂志(影响因子:11.3)在线发表。传统观点认为,女性和绝大多数雌性哺乳动物卵母细胞的产生仅发生在胎儿期,出生后卵母细胞数目不再增加,反而逐年减少,这意味着出生后卵巢无

科技部:2017“干细胞及转化研究”国家重点研发计划专项指南出炉(附全文)

关于对国家重点研发计划干细胞及转化研究等6个重点专项2017年度项目申报指南征求意见的通知 根据《国务院关于改进加强中央财政科研项目和资金管理的若干意见》(国发[2014]11号)、《国务院关于深化中央财政科技计划(专项、基金等)管理改革方案的通知》(国发[2016]64号)、《科技部 财政部关于改革过渡期国家重点研发计划组织管理有关事项的通知》(国科发资[2015]423号)等文件要求,现

全国首例胎盘干细胞治疗骨关节炎临床应用获成功

8月,江苏大学附属医院“收治”的一名骨关节炎患者在历经为期 7个月的胎盘间充质干细胞治疗后,已达到预期治疗效果。据悉,这是江苏大学附属医院与博雅干细胞合作实施的全国首例应用胎盘干细胞治疗骨关节炎,是胎盘干细胞技术在骨关节炎领域的全新突破。 证实:胎盘干细胞可促进骨关节软骨损伤修复 骨关节炎是一种退行性病变,由于关节软骨退化损伤和破坏等引起,在60岁以上的人群中患病率可

PNAS:干细胞治疗可缓解眼压降低青光眼风险

近日,来自美国爱荷华大学的研究人员发表一项最新研究进展,他们向青光眼小鼠模型的眼内输注利用干细胞分化得到的小梁网状细胞能够帮助解决流体堵塞问题重新恢复适当的液体流出,这样可以降低眼压从而降低青光眼患病风险。 研究人员将新生细胞注射到青光眼小鼠模型的眼内,发现新细胞的流入能够帮助小梁网状结构再生,该结构是眼部的一个排水管道能够帮助避免出现液体累积,如果液体在眼睛里累积会使眼压升高容易导致青

Baidu
map
Baidu
map
Baidu
map